LFB Biotechnologies
GTC has entered into a collaboration agreement with LFB to develop selected recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform. Under this agreement, GTC will share equally with LFB in the cost of the development and commercialization of each product and will be entitled to 50% of any profits derived from products developed through the collaboration. GTC will be responsible for development of the production system for the products and will retain exclusive commercial rights to the products in North America. LFB will be responsible for clinical development and regulatory review of the programs in this collaboration, and will have exclusive commercial rights in Europe. GTC will hold co-exclusive rights with LFB in the rest of the world to any products developed through the collaboration. GTC and LFB are currently developing a recombinant human Factor VIIa, a recombinant human Factor IX and a monoclonal antibody to CD20.

Lundbeck (formerly Ovation Pharmaceuticals)
GTC has entered into a collaboration agreement with Lundbeck Inc. (formerly OVATION Pharmaceuticals, Inc.) to develop and market ATryn® in the United States in the hereditary antithrombin deficiency, or HD, indication. The collaboration also plans for further development in larger market acquired antithrombin deficiencies such as the treatment of heparin resistance in patients undergoing surgery requiring cardiopulmonary bypass.